SCHEMBL6038864

SCHEMBL6038864

N#Cc1ccc(S(=O)(=O)Nc2nc3ccccc3nc2OCCCc2ccccn2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.54
MEN1 O00255 4/20 0.54
KDM4E B2RXH2 5/20 0.50
LMNA P02545 1/20 0.50
HSD17B10 Q99714 1/20 0.50
HSD11B1 P28845 6/20 0.48
PIK3CG P48736 1/20 0.46
GLO1 Q04760 1/20 0.43
RXFP1 Q9HBX9 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
HDAC3 O15379 1/20 0.42
HDAC4 P56524 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC7 Q8WUI4 1/20 0.42
HDAC2 Q92769 1/20 0.42
HDAC10 Q969S8 1/20 0.42
HDAC11 Q96DB2 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
HDAC9 Q9UKV0 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6038824 0.95 MEN1 (0.55) KMT2AMEN1KDM4ELMNAHSD17B10
SCHEMBL6038585 0.89 KDM4E (0.53) KMT2AMEN1KDM4ELMNAHSD17B10
SCHEMBL6038999 0.89 KDM4E (0.63) KMT2AMEN1KDM4ELMNAHSD17B10
SCHEMBL6038967 0.87 KMT2A (0.60) KMT2AMEN1KDM4ELMNAHSD17B10
SCHEMBL6038810 0.87 KMT2A (0.57) KMT2AMEN1KDM4ELMNAHSD17B10
SCHEMBL6038649 0.87 KMT2A (0.57) KMT2AMEN1KDM4ELMNAHSD17B10
SCHEMBL6039061 0.85 KMT2A (0.60) KMT2AMEN1KDM4ELMNAHSD17B10
SCHEMBL6038638 0.84 KMT2A (0.56) KMT2AMEN1KDM4ELMNAHSD17B10
SCHEMBL6038754 0.84 MEN1 (0.52) KMT2AMEN1KDM4ELMNAHSD17B10
SCHEMBL6038604 0.84 KMT2A (0.58) KMT2AMEN1KDM4ELMNAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060004010-A1 Ccr4 antagonist and medical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2006-01-05 US disclosed
EP-1541563-A1 CCR4 ANTAGONIST AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004010-A1 Ccr4 antagonist and medical use thereof CCR4, CCR1, CCR9 KMT2A 4190/4885MEN1 2431/4885KDM4E 3561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.